World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
57
Citations
12958
World Ranking
3607
National Ranking
1670

Overview

Andrew D. Weinberg is affiliated with Providence Portland Medical Center in the United States. Their research primarily focuses on fields within medicine, notably immunology and microbiology, with a significant portion dedicated to oncology.

The scientist's research covers several interconnected subfields, including immunology, oncology, infectious diseases, molecular biology, and biotechnology. This interdisciplinary approach supports investigations into immune system mechanisms and therapeutic interventions.

Main topics covered in their work include:

  • CAR-T cell therapy research
  • Immunotherapy and immune responses
  • Cancer immunotherapy and biomarkers
  • Immune cell function and interaction
  • SARS-CoV-2 and COVID-19 research
  • T-cell and B-cell immunology
  • Immune cells in cancer

Andrew D. Weinberg has been published in various academic venues. Frequent publication venues include:

  • Regular and Young Investigator Award Abstracts
  • The Journal of Immunology
  • Cell
  • Nature Communications
  • Journal of Clinical Investigation

Significant recent papers authored or coauthored by Weinberg include:

  • "T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants," 2023, Cell
  • "Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells," 2021, Nature Communications
  • "PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors," 2022, Journal of Clinical Investigation
  • "OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines," 2022, Frontiers in Immunology
  • "959 PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors," 2022, Regular and Young Investigator Award Abstracts

The scientist frequently collaborates with several other researchers in their domain. Frequent coauthors include:

  • Rebekka Duhen
  • Eric Tran
  • Colin Thalhofer
  • Bernard A. Fox
  • Michael Beymer

Best Publications

  • Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

    Thomas Duhen;Rebekka Duhen;Ryan Montler;Jake Moses

  • Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses

    Irene Gramaglia;Andrew D. Weinberg;Michael Lemon;Michael Croft

  • The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion.

    Irene Gramaglia;Amha Jember;Susanne D. Pippig;Andrew D. Weinberg

  • OX40 is a potent immune-stimulating target in late-stage cancer patients.

    Brendan D. Curti;Magdalena Kovacsovics-Bankowski;Nicholas Morris;Edwin Walker

  • Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development.

    Susan L. Swain;Linda M. Bradley;Michael Croft;Susan Tonkonogy

  • Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

    Barbara Valzasina;Cristiana Guiducci;Cristiana Guiducci;Heidrun Dislich;Heidrun Dislich;Nigel Killeen;Nigel Killeen

  • Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity

    Andrew D. Weinberg;Martin Muy Rivera;Rodney Prell;Arden Morris

  • Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40

    Kazuo Sugamura;Naoto Ishii;Andrew D. Weinberg

  • Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis.

    Andrew D. Weinberg;Keith W. Wegmann;Keith W. Wegmann;Castle Funatake;Ruth H. Whitham;Ruth H. Whitham

  • Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion.

    Joseph R. Maxwell;Andrew Weinberg;Rodney A. Prell;Anthony T. Vella

  • OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

    Daniel Hirschhorn-Cymerman;Gabrielle A. Rizzuto;Taha Merghoub;Adam D. Cohen

  • Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

    Jørgen Kjærgaard;Junta Tanaka;Julian A. Kim;Kevin Rothchild

  • T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants

    Unknown

  • The role of OX40-mediated co-stimulation in T-cell activation and survival.

    William L. Redmond;Carl E. Ruby;Andrew D. Weinberg

  • OX-40: life beyond the effector T cell stage.

    Andrew D. Weinberg;Anthony T. Vella;Michael Croft

  • Science gone translational: the OX40 agonist story.

    Andrew D. Weinberg;Nicholas P. Morris;Magdalena Kovacsovics-Bankowski;Walter J. Urba

  • Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

    Carl E. Ruby;Melissa A. Yates;Melissa A. Yates;Daniel Hirschhorn-Cymerman;Peter Chlebeck

  • OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

    Michael J. Gough;Carl E. Ruby;William L. Redmond;Birat Dhungel

  • The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

    Amy E Moran;Magdalena Kovacsovics-Bankowski;Andrew D Weinberg

  • OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines.

    Andrew D. Weinberg

  • Signaling through OX40 enhances antitumor immunity.

    Shawn M. Jensen;Levi D. Maston;Michael J. Gough;Carl E. Ruby

Frequent Co-Authors

Walter J. Urba
Walter J. Urba Providence Portland Medical Center
Bernard A. FoxEarle
Bernard A. FoxEarle Earle A. Chiles Research Institute
Michael J. Gough
Michael J. Gough Providence Portland Medical Center
Suyu Shu
Suyu Shu University of Michigan–Ann Arbor
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
David C. Parker
David C. Parker Oregon Health & Science University
Michael Croft
Michael Croft La Jolla Institute For Allergy & Immunology
Louis J. Picker
Louis J. Picker Oregon Health & Science University
Anthony T. Vella
Anthony T. Vella University of Connecticut Health Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in branching out from Immunology, nursing offers a practical and in-demand career path. Many turn to 12-month accelerated nursing programs online for non nurses to quickly transition into healthcare roles without prior nursing experience.

If securing admission is a concern, exploring absn programs with high acceptance rates could be a strategic choice. These programs help more students enter the nursing field with less competition, making the journey smoother.

For entry-level nursing careers, easy admission lpn programs provide a quicker route to become a Licensed Practical Nurse. These are ideal for those seeking hands-on patient care roles with shorter training periods.

For advanced practice opportunities, looking into the easiest np programs to get into can streamline the path to becoming a Nurse Practitioner. These programs combine flexibility with accessibility, allowing graduates to take on greater responsibilities in healthcare settings.

Best Scientists Citing Andrew D. Weinberg

Trending Scientists